Quantcast

Latest Sodium-glucose transport proteins Stories

2014-01-29 16:29:02

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/2qlc2k/lexicons_lx4211) has announced the addition of the "Lexicon's LX4211 - FDA canagliflozin decision is key bellweather" [http://www.researchandmarkets.com/research/2qlc2k/lexicons_lx4211 ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) LX4211 is part of a new class of type 2 diabetes agents that inhibit the SGLT2...

2011-06-27 05:00:00

THE WOODLANDS, Texas, June 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company presented clinical data from a mechanistic study of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), in patients with type 2 diabetes at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, California....

2011-01-06 05:00:00

THE WOODLANDS, Texas, Jan. 6, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2). Results from the study demonstrated that administration of a 300 mg solid oral tablet dose of...

2010-06-28 07:00:00

TOKYO, June 28 /PRNewswire/ -- Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori, "Astellas") announced that the company presented results from a Japanese Phase 2 study conducted with ASP1941, a selective SGLT2 inhibitor, at the 70th Scientific Sessions of the American Diabetes Association (ADA) on June 26, 2010 (EST). ASP1941 is designed to block the re-absorption of glucose in the kidney and excrete glucose in the urine. The oral presentation, along with...

2010-06-21 17:00:00

THE WOODLANDS, Texas, June 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as...

2010-06-15 18:00:00

THE WOODLANDS, Texas, June 15 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will be presenting clinical data from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010: The 92nd Annual Meeting and Expo, June 19 - 22, 2010 in San Diego, California and the 70th Scientific Sessions of the American Diabetes...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.